Anzeige
Mehr »
Login
Dienstag, 22.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Der Megatrend 2025: Die unterschätzte Chance im Uranmarkt - was diese Aktie JETZT interessant macht!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DSXP | ISIN: SE0009723125 | Ticker-Symbol: 65G
Frankfurt
22.04.25
08:19 Uhr
0,073 Euro
+0,009
+13,55 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXTCELL PHARMA AB Chart 1 Jahr
5-Tage-Chart
NEXTCELL PHARMA AB 5-Tage-Chart

Aktuelle News zur NEXTCELL PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.04.NextCell Pharma AB: NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward49NextCell Pharma ("the company" or "NextCell") has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the...
► Artikel lesen
NEXTCELL PHARMA Aktie jetzt für 0€ handeln
07.04.NEXTCELL PHARMA AB: Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young1
28.03.NEXTCELL PHARMA AB: NextCell's CSO Appointed to the Board of ATMP Sweden5
19.03.NEXTCELL PHARMA AB: Recognition for NextCell's CSO from the International Society of Cell and Gene Therapy1
13.03.NextCell Pharma AB: Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv350NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient in the older age cohort (12-21 years) of the clinical Phase II study, ProTrans-Young, has now completed their 12-month...
► Artikel lesen
19.02.NEXTCELL PHARMA AB: All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study1
30.01.NextCell Pharma AB: NextCell Pharma publish Interim Report 1 2023/2024126NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 - November 30, 2024. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report....
► Artikel lesen
17.12.24NEXTCELL PHARMA AB: Long-term Effects with Repeated ProTrans Treatment After 6 Years1
05.12.24NEXTCELL PHARMA AB: NextCell Pharma changes Certified Adviser to Redeye AB4
25.11.24NEXTCELL PHARMA AB: QVance's Partnerships Driving Innovation in Advanced Therapies1
18.11.24NEXTCELL PHARMA AB: QVance Announces Partnership2
08.11.24NEXTCELL PHARMA AB: QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT2
04.11.24NextCell Pharma AB participates in BIO-Europe 2024 and welcomes a visit from Minister Ebba Busch1
24.10.24NextCell Pharma AB: NextCell publishes its Year-End Report 2023/202490NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2023 - August 31, 2024. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report....
► Artikel lesen
12.07.24Nasdaq Stockholm AB: New equity rights for trading, NextCell Pharma AB TO 2322At the request of NextCell Pharma AB, NextCell Pharma AB's equity rights will be traded on First North Growth Market as from July 15, 2024. Securit NextCell Pharma AB TO 2 ...
► Artikel lesen
27.05.24XFRA CAPITAL ADJUSTMENT INFORMATION - 27.05.2024973Das Instrument 37P FR0010341032 FONCIERE INEA SA EO 14,39 EQUITY wird ex Kapitalmassnahme gehandelt am 27.05.2024 The instrument 37P FR0010341032 FONCIERE INEA SA EO 14,39 EQUITY is traded ex capital...
► Artikel lesen
25.04.24NextCell Pharma AB: NextCell publishes its Interim Report 2 2023/2024166NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2023 - Februari 29, 2024. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report....
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1